Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly ...

"We launched the Humankind 100 four years ago to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress," said James ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.